Biogen Inc. (BIIB) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Christopher A. Viehbacher.
BIIB has IPO date of 1991-09-17, 7,605 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $26.26B.
Biogen Inc. is a global biopharmaceutical company founded in 1978 and headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. The company maintains a robust portfolio of approved treatments across multiple therapeutic areas, including multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (ADUHELM), and oncology and immunology indications (RITUXAN, GAZYVA), alongside a growing biosimilar franchise featuring etanercept, adalimumab, and infliximab biosimilars. Beyond its marketed products, Biogen maintains an extensive pipeline of investigational therapies targeting neurological disorders, including candidates for multiple sclerosis, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, and immunology-related conditions. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Genentech, Eisai, Ionis Pharmaceuticals, and Sage Therapeutics to advance its research and development initiatives across its core therapeutic focus areas.
